Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 4126 in Acromegaly and GEP-NETs
NCT05364944Phase 1Terminated
- Sponsor
- Debiopharm
- Start
- May 2022
- Primary completion
- Oct 2024
- Modality
- Drug Delivery Systems
- Countries
- 8
01
Overview
Phase 1, open-label trial of Debio 4126 in acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (2 cohorts), sponsored by Debiopharm. Primary endpoint: Plasma Concentration of Debio 4126. Started May 2022; status: terminated.
02
Drugs
Debio 4126
03
Conditions
acromegalygastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Beyond the preview
Go deeper on NCT05364944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364944.